News from the Innovative Medicines for Tuberculosis Foundation

11 Jun 2019 – The trial with panel C has started, aiming at evaluating the safety and tolerability of PBTZ169 at a dose of 600 mg, once a day for 14 days, in healthy volunteers.

27 May 2019 – The Trial Safety Board assessed the safety and tolerability parameters for panels A and B, and authorized dose escalation as no salient adverse events were observed with PBTZ169 300 mg administered b.i.d. for 2 weeks. The trial will continue with panel C (600 mg q.d.) scheduled for June 2019.

11 Mar 2019 – The phase Ib trial (multiple ascending doses) officially started, dose escalation will be performed through 4 panels A, B, C and D.

26 Jun 2018 – PBTZ169 has been named Macozinone. Read more here.

28 Mar 2018 – The phase Ia clinical trial with PBTZ169 is completed and the collected safety data, as well as pharmacokinetic and pharmacodynamic parameters, are being analyzed.

16 Mar 2018 – The first three investigation panels of the Phase Ia clinical trial have been successfully completed. The fourth and final panel has started and healthy male volunteer recruitment is complete.

01 Jan 2018 – Dr. Stewart Cole, Chair of the iM4TB Foundation board and co-founder named head of illustrious Institut Pasteur

01 Jan 2018 – The Year in Review, what happened at iM4TB in 2017

05 Dec 2017 – Start of Phase Ia clinical trial with single ascending dose The trial is divided into 4 investigation panels.

24 Apr 2017 – The Bill & Melinda Gates Foundation has awarded $2.45M to take our PBTZ169 into clinical trials

30 Nov 2015 – NEARMEDIC Plus wins the silver medal of the Suvorov Prize 2015

01 Nov 2015 – Dr Antonia Di Micco joins the Foundation iM4TB for 6 months to help preparing Regulatory documents required for the submission of a Clinical Trial Application for a clinical study with PBTZ 169 next year

07 May 2015 – Innovative Medicines for Tuberculosis (iM4TB) Foundation announces Nobel Prize Winner Françoise Barré-Sinoussi as Patron

16 March 2015 – iM4TB receives major grant from the Bill & Melinda Gates Foundation

19 January 2015 – Prof. Stewart Cole elected to French National Academy of Pharmacy

25 July 2014 – EPFL joins forces with pharmaceutical company to fight tuberculosis in most countries of the former Russian Federation


Media coverage – Print

Financial Times
Financial Times  – Genetics offers route to cure tuberculosis



MedicalPressLogoMedical Press – New and extremely promising antibiotic for tuberculosis


DrugDiscoveryLogoDrug Discovery & Development – New TB antibiotic help kill multi-resistant strains


nm-logo-2News Medical – EPFL sets up foundation to release antibiotic for tuberculosis


Media coverage – Audio/video


RTS – Radio Télévision Suisse – Tuberculose – histoire évolutive et bactérie zombie (in french)


RTS – Radio Télévision Suisse – L’histoire de certaines épidémies serait liée à certains grands événements politiques (in french)

WRG World Radio Geneva – listen to interview

logo-rtsRTS – Radio Télévision Suisse – listen to interview (in french)

La Télé – Swiss Regional Television – watch broadcast interview (in french)

logo-rtsRSR – Radio Suisse Romande – listen to interview (in french)





<script> (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//','ga'); ga('create', 'UA-50449259-1', 'auto'); ga('send', 'pageview'); </script>